A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants

NCT01458210 · Completed

Last updated 2026-05-28

This study tests how the diabetes medication dulaglutide affects the way the body processes the birth control pill Ortho-Cyclen in healthy women.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 22 people

Who can join Ages 18–45 · female only Healthy volunteers accepted.

Timeline Started 2011-10 · est. completion 2012-02

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT01458210 ↗

Description as written by the study sponsor.

The purpose of this study is to look at how the body processes oral contraceptive (OC), using Ortho-Cyclen, as a commonly prescribed combination oral contraceptive in healthy female participants, and the effect of dulaglutide on how Ortho-Cyclen is processed by the body. Information about any side effects that may occur will also be collected.

Treatments tested

Ortho-Cyclen Drug

Administered orally
Dulaglutide also known as LY2189265 Biologic

Administered subcutaneously

Main thing measured	Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) at Steady State of Ortho-Cyclen - Norelgestromin (NGMN)
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01458210 ↗